Tumour vasculature as a target fer cancer therapy

British Journal of Cancer

Volumn 80, Issue SUPPL. 1, 1999, Pages 57-64

  Chaplin, D J ^a,c   Dougherty, G J ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COMBRETASTATIN; DIMETHYLXANTHENONE ACETIC ACID; GAMMA INTERFERON; MITOFLAXONE; PODOPHYLLOTOXIN; TUBULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CONFERENCE PAPER; GENE THERAPY; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; RETROVIRUS; TISSUE SPECIFICITY; TUMOR VASCULARIZATION;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032773566     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (103)

1. Adams GE and Stratford IJ (1994) Bioreductive drugs for cancer therapy. The search for tumor specifically. Int J Radiat Oncol Biol Physics 29: 231-238
2. Ager S, Nilson BH, Morling FJ, Peng KW, Cosset FL and Russell SJ (1996) Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Human Gene Therapy 7: 2157-2164
3. Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB and Rosenburg RD (1995) Human von Willbrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci USA 92: 4567-4571
4. Algire GH, Legallais FY and Anderson BF (1954) Vascular reactions of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas. J Natl Cancer Inst 14: 879-887
5. Asman DC, Dirks JF, Ge L, Resnick NM, Salvucci LA, Gau J, Becieh MJ, Cooper DL and Dougherty, GJ (1995) Gene therapeutic approach to primary aiul metastatic brain tumors: 1, CD44 variant pre-mRNA alternative splicing as a CEPT control element. J Neuro-Oncol 26: 243-250
6. Baguley BC, Holdaway KH, Thomsen LL, Zhuang L and Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism. Eur J Cancer 27: 482-487
7. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE and Brindle KE (1998) MRI and MRS of Combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status. Br J Cancer 77: 1761-1767
8. Bibby MC, Double JA, Loadman PM and Duke CV (1989) Reduction of tumor blood flow by flavone acetic acid; a possible component of therapy. J Natl Cancer Inst 81: 216-220
9. Boyland E and Boyland ME (1937) Studies in tissue metabolism. IX. The action of colchine and B. typhosus extract. Biochem J 31: 454-460
10. Brody SL and Crystal RG (1994) Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 716: 90-101
11. Brooks PC, Clark RAF and Cherish DA (1994) Requirement of vascular integrin avb3 for angiogenesis, Science 264: 569-571
12. 3, antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
13. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822
14. Burrows FJ and Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA 90: 8996-9000
15. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF and King SW (1995) Endoglin is an endothelial cell proliferation marker that is upregulated in tumor vasculature. Clin Cancer Res 1: 1623-1634
16. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B (1975) An endotoxin-induced serum factor that causes necrosis, of tumors. Proc Natl Acad Sci USA 72: 3666-3670
17. Chaplin DJ and Horsman MR (1994) The influence of tumour temperature on ischemia induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol 30: 59-65
18. Chaplin DJ, Olive PL and Durand RE (1987) Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 47: 597-601
19. Chaplin DJ, Pettit GR, Parkins CS and Hill SA (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74: 586-588.
20. Chen CY and Shyu AB (1995) AU-rich elements; characterisation and importance in mRNA degradation. Trends Biochem Sci 20: 465-470
21. Ching LM, Joseph WR, Crosier KE and Baguley BC (1994) Induction of tumor necrosis factor α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6 dimethylxanthenone 4-acetic acid (NSC64088). Cancer Res 54: 870-872
22. Chu TT, Martinez I, Sheay WC and Dornburg R (1994) Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Therapy I: 292-299
23. Coley Nauts H, Fowler GA and Bogatko FH (1993) A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumors in man. Acta Medica Scand 274: 29-97
24. Cowan PJ, Shinkel TA, Wilfort EJ, Barlow H, Pearse MJ and d'Apice AJ (1996) Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter, Transplantation 62: 155-160
25. Culver KW, Ram Z, Wallbridge S, Ishill H, Oldfield EH and Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552
26. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ and Harris Al. (1997) Targeting gene expression to hypoxic tumor cells, Nat Med 3: 515-520
27. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ (1997) Combretastatin A4. An agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 57: 1829-1834
28. Denekamp J (1986) Endothelial cell attack as a novel approach to cancer therapy. Cancer Topics 6: 6-8
29. Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Met Rev 9: 267-282
30. Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiother 66: 181-196
31. Denekamp J, Hill SA and Hobson B (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19: 271-275
32. Denis LJ and Verweij J (1997) Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 15: 175-185
33. Deonaram MP, Spooner RA and Epenetos AA (1995) Genetic delivery of enzymes of cancer therapy. Gene Therapy 24: 235-244
34. Derbeyshire EJ and Thorpe PE (1997) Targeting the tumour endothelium using specific antibodies. In: Tumour Angiogenesis, Bicknell R, Lewis CE and Ferraro N (eds), pp. 343-356, Oxford; Oxford University Press
35. Dichek DA, Lee SW and Nguyen NH (1994) Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. Blood 84: 504-516
36. Dougherty GJ, Peters CE, Dougherty ST, McBride WH and Chaplin DJ (1996) Gene therapy based approaches to the treatment of cancer. Development of targetable retroviral vectors. Transfusion Sci 17: 121-128
37. Douglas JT and Curiel DT (1997) Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromusc Disorders 7: 284-298
38. Dvorak HF, Sioussat TM, Brown LF, Berise B, Nagy JA, Sotrel A, Manseau EJ, Van De Water L and Senger DR (1991) Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumour blood vessels. J Expt Med 174: 1275-1278
39. Eggermont AM, Schraffordt Koops H. Klausner JM, Lienard D, Kroon BB, Schlag PM, Ben-Ari G and Lejeune FJ (1997) Isolation limb perfusion with tumour necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Semin Oncol 24: 547-555
40. Falgout B and Ketner G (1988) Characterization of adenovirus particles made by detection mutants lacking the fiber gene. J Virol 62: 622-625
41. Fan TP, Jaggar R and Bicknell R (1995) Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16: 57-66
42. Gallardo D, Drazan KE and McBride WH (1996) Adenovirus-based transfer of wild-type p53 increases ovarian tumor radiosensitivity. Cancer Res 56: 4891-4393
43. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Band A, Campain JA and Curiel DT (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57: 1447-1451
44. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE and Finkel T (1993) Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 88: 2838-2848
45. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW and Weichelbaum RR (1995) Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1: 786-791
46. Harats D, Kurihara H, Belloni P, Oakley H, Ziober Z, Ackley D, Cain G, Kurihara Y, Lawn R and Sigal E (1995) Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 95: 1335-1344
47. Hill SA, Longergan SJ, Denekamp J and Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29: 1320-1324
48. Hill SA, Sampson LE and Chaplin DJ (1995) Antivascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119-123
49. Hill SA, Pigott KH, Saunders MI, Powell MEB, Arnold S, Obeid A, Ward G, Leahy M, Hoskin PJ and Chaplin DJ (1996) Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer 74: S260-S263
50. Huang S, Endo RI and Nemerow GR (1995) Upregulation of integrins avb3 and avb5 on human monocytes and T lymphocytes facilities adenovirus-mediated gene delivery. J Virol 69: 2257-2263
51. Huang X, Molema G, King S, Watkins L, Edgington TS and Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumour vasculature. Science 24: 547-550
52. Hunter E and Swanstrom R (1990) Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 157: 187-253
53. Jahroudi N and Lynch DC (1994) Endothelial cell specific regulation of von Willebrand factor gene expression. Mol Cell Biol 14: 999-1008
54. Jejurikar SS, Welling TH, Zelenock JA, Gordon D, Burkel WE, Carlson BM and Messina LM (1997) Induction of angiogenesis by lidocaine and basic fibroblast growth factor; a model for in vivo retroviral-mediated gene therapy. J Surg Res 67: 137-146
55. Kallinowski F, Schaefer C, Tyler G and Vaupel P (1989) In vivo targets of recombinant human tumour necrosis factor α, blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60: 555-560
56. Karsan A, Yec E and Harlan JM (1996) Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, AI. J Biol Chem 271: 27201-27204
57. Kasahara N, Dozy AM and Kan YW (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376
58. Kerr DJ, Maughan T, Newlands E, Rustin G, Bleehen NM, Lewis C and Kaye SB (1989) Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal cancer. Br J Cancer 60: 104-106
59. Kimura H, Braun RD, Ong ET, Hsu R, Secombe TW, Papahadjopoulos D, Hong K and Dewhirst MW (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56: 5522-5528
60. Ludford RJ (1945) Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 6: 89-101
61. Ludford RJ (1948) Factors determining the action of colchicine on tumour growth. Br J Cancer 2: 75-86
62. McBride WH and Dougherty GJ (1995) Radiotherapy for genes that cause cancer. Nat Med 1: 1215-1217
63. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP and Hart IR (1990) Role of tumour necrosis factor in flavone acetic acid induced tumor vasculature shutdown. Cancer Res 50: 5537-5542
64. Marshall JL and Hawkins MJ (1995) The clinical experience with antiangiogenic agents. Breast Cancer Res Treat 36: 253-261
65. Maughan TS, Ward R, Dennis I, Honess DJ, Workman P and Blechen NM (1992) Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data. Br J Cancer 66: 579-582
66. Miller DG, Adam MA and Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239-4242
67. Miller N and Vile R (1995) Targeted vectors for gene therapy. FASEB J 9: 190-199
68. Morishita K, Johnson DE and Williams LT (1995) A novel promoter for vascular endothelial growth factor receptor (fl101) that confers endothelial-specific gene expression. J Biol Chem 270: 27948-27953
69. Moses MA and Langer R (1991) Inhibitors of angiogenesis. Biotechnology 9: 630-634
70. Mottram JC (1928) Observations on the combined action of colloidal lead and radiation on tumours. Br Med J 1: 928
71. Neri D, Carnemolia B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15: 1271-1275
72. Ohno K, Sawai K, Lijima Y, Levin B and Meruelo D (1997) Cell-specific targeting of Sindis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 15: 763-767
73. O'Reilly MS, Holmgren L, Chen C and Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692
74. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
75. Pahl HL and Baeuerle PA (1994) Oxygen and control of gene expression. BioEssays 16: 497-502
76. Parentesis JP, Miller SP and Bodley JW (1992) Protein toxin inhibitors of protein synthesis. Biofactory 3: 173-184
77. Pasqualini R and Rouslahti F. (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366
78. Pasqualini R, Kolvunen F. and Ruoslahti E (1997) Alpha-v integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnology 15: 542-546
79. Penstero MN, Wysocki CA, Nader K and Kikuchi GE (1996) Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Human Gene Therapy 7: 1095-1101
80. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM and Oldfield EH (1994) The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81: 256-260
81. Ross J (1996) Control of messenger RNA stability in higher eukaryotes. Trends Genet 12: 171-175
82. Russell SJ, Hawkins RE and Winter G (1993) Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21: 1081-1085
83. Schlaeger TM, Qin Y, Fujiwara Y, Magram J and Sato TN (1995) Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121: 1089-1098
84. Schnierle BS and Groner B (1996) Retroviral targeted delivery. Gene Therapy 3: 1069-1073
85. Seed L, Slaughter DP and Limarzi LR (1940) Effect of colchicine on human carcinoma. Surgery 7: 696-709
86. Stephens TC, Courtenay VC, Mills J, Peacock JH, Rose CM and Spooner D (1981) Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenografi by the combination of cytotoxic drugs and misonidazole Br J Cancer 43: 451-457
87. Strawn LM, McMahon G, App H, Schreck R, Huchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I. Ulrich A, Hirth KP and Shawver LK (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545
88. Twardowski P and Gradishar WJ (1997) Clinical trials of antiangiogenic agents. Curr Opin Oncol 9: 584-589
89. Tzeng E, Shears LL, Robbins PD, Pitt BR, Geller DA, Watkins SC, Simmons RL and Billicar TR (1996) Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med 2: 211-225
90. Walsh (1844) The Anatomy, Physiology, Pathology and Treatment of Cancer. London:
91. Wang J and Manley JL (1997) Regulation of pre-mRNA splicing in metazoa. Current Opinion in Genetics & Development 7: 205-211
92. Watts ME, Woodcock M, Arnold S and Chaplin DJ (1997) Effects of novel and conventional anti-cancer agents on human endothelial cell permeability: Influence of tumour secreted factors. Anticancer Res 147: 329-334
93. Weichselbaum RR, Hallahan DE, Sukhatme VP and Kufe DW (1992) Gene therapy targeted by ionizing radiation. Int J Rad Oncol Biol Phys 24: 565-567
94. Weiss RA (1993) Cellular Receptors and Viral Glycoproteins Involved in Retrovirus Entry. New York: Plenum Press.
95. Welsh RM, Cooper NR, Jensen FC and Oldstone MBA (1975) Human serum lyses RNA tumour viruses. Nature 257: 612-614
96. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319
97. Wickham TJ, Filardo EJ, Chesesh DA and Nemerow, GR (1994) Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 127: 257-264
98. Wickham TJ, Carrion ME and Kovesdi I (1995) Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifis, Gene Therapy 2: 750-756
99. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM and Kovesdi 1 (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70: 6831-6838
100. Woglum WH (1923) A critique of tumour resistance. J Cancer Res 7: 283-311
101. Zelenock JA, Welling TH, Sarkar R, Gordon DG and Messina LM (1997) improved retroviral transduction efficiency of vascular cells in vitro and in vivo during clinically relevant incubation periods using centrifugation to increase viral titers. J Vasc. Surg 26: 119-127
102. Ziche M, Corrallini A, Possati L, Vacca A, Ribbatti D and Presta M (1996) Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Diff 7: 147-160
103. Zwi LJ, Baguley BC, Gavin JB and Wilson WR (1989) Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid. J Natl Cancer Inst 81: 1005-1013